Table 1.
Demographic, clinical and virological features of the 82 HIV-HCV co-infected patients who fulfilled the inclusion criteria
| Variables | Results |
|---|---|
| Age (years)1 |
48 (±6) |
| Male, n (%)2 |
62 (75.6) |
| HCV Genotype 1, n (%)2 |
48 (58.5) |
| Previous HCV therapy, n (%)2 |
17 (20.7) |
| Advanced liver fibrosis, n (%)2 |
19 (23.2) |
| CD4 cell count at T11 (cells/mm3) |
576 (±280) |
| CD4 cell count at T21 (cells/mm3) |
654 (±351) |
| HCV RNA at T11 (IU/ml) |
3924650 (±5320177) |
| HCV RNA at T21 (IU/ml) |
3085128 (±3372347) |
| Ongoing ART at T22, n (%) |
73 (89) |
| Clean IFU, n (%)2 |
39 (47.6) |
| Clean FFU5, n (%)2 |
57 (69.5) |
| Discordant HIV RNA suppression at IFU4, n (%) |
14 (17.1) |
| IL 28B CC genotype, n (%)2 | 20 (31.7) |
1mean and SD; 2absolute number and percentage respect to all included patients.
ART: Anti Retroviral Therapy; Clean IFU: HIV viremia undetectable during initial follow-up (0-24 months from T1), regardless of being on ART; Clean FFU: HIV viremia undetectable during final follow-up (24-36 months from T1), regardless of being on ART.
Data on IL28B genotype were available for the 63 patients (76.8%).